$NGN

Niagen Bioscience has made a strategic pivot towards telehealth services, aimed at enhancing patient access and engagement. This shift is expected to increase revenue streams and broaden their market reach, making the company a more attractive investment. The telehealth sector is witnessing significant growth, particularly post-pandemic, aligning with consumer preferences for convenient healthcare solutions. Analysts suggest that Niagen's transition positions it well against competitors still reliant on traditional in-person models. As a result, the company is being labeled a strong buy by industry experts.